Scarica l'app Stockscreener
2.57
1.15%
-0.03
Dopo l'orario di chiusura:
2.57
Spero Therapeutics Inc Borsa (SPRO) Ultime notizie
Will Spero Therapeutics Inc. stock benefit from upcoming earnings reports2025 Trade Ideas & Free Expert Verified Stock Movement Alerts - ulpravda.ru
Will Spero Therapeutics Inc. (2HA) stock sustain bullish trend into 2025Quarterly Earnings Summary & AI Forecast for Swing Trade Picks - ulpravda.ru
Spero Therapeutics (NASDAQ:SPRO) Downgraded by Wall Street Zen to Hold - MarketBeat
What analysts say about Spero Therapeutics Inc stockLong-Term Growth Stocks & Free Unmatched Market Gains - earlytimes.in
Spero Therapeutics (NASDAQ:SPRO) Stock Crosses Below 200-Day Moving Average – Here’s What Happened - Defense World
Spero Therapeutics (NASDAQ:SPRO) Stock Crosses Below 200-Day Moving AverageHere's What Happened - MarketBeat
Spero Therapeutics, Inc. (NASDAQ:SPRO) Sees Large Growth in Short Interest - MarketBeat
Book value per share of Spero Therapeutics, Inc. – BER:2HA - TradingView — Track All Markets
Spero Therapeutics (STU:2HA) EV-to-OCF : -2.75 (As of Dec. 24, 2025) - GuruFocus
Spero Therapeutics (NASDAQ:SPRO) Stock Price Crosses Below 200 Day Moving AverageTime to Sell? - MarketBeat
Spero Therapeutics (NASDAQ:SPRO) Stock Price Crosses Below 200 Day Moving Average – Time to Sell? - Defense World
Will Spero Therapeutics Inc. stock reach all time highs in 2025Inflation Watch & Growth Oriented Trade Recommendations - Улправда
Stop Loss: Will Spero Therapeutics Inc. stock reach all time highs in 2025Inflation Watch & Reliable Price Breakout Signals - ulpravda.ru
GSK, Spero Therapeutics resubmits NDA for tebipenem HBr as oral option for complicated urinary tract infections - Contemporary OB/GYN
GSK Resubmits NDA, Triggering Milestone for Spero Therapeutics - TipRanks
Spero Therapeutics Announces NDA Resubmission for Tebipenem HBr - TradingView — Track All Markets
Spero Therapeutics Announces GSK's NDA Resubmission for Tebipenem HBr, Triggering $25 Million Milestone Payment - Quiver Quantitative
Spero Announces NDA Resubmission of Tebipenem HBr by GSK to - GlobeNewswire
How geopolitical risks impact Spero Therapeutics Inc. (2HA) stockMarket Performance Report & Short-Term Trading Opportunity Alerts - DonanımHaber
Total debt per share of Spero Therapeutics, Inc. – FWB:2HA - TradingView — Track All Markets
Is Spero Therapeutics (NASDAQ:SPRO) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Spero Therapeutics (SPRO) price target decreased by 20.00% to 4.08 - MSN
Spero Therapeutics (NASDAQ:SPRO) Upgraded to "Buy" at Wall Street Zen - MarketBeat
Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue Estimates - sharewise.com
Spero Therapeutics (NASDAQ:SPRO) Stock Rating Lowered by Wall Street Zen - MarketBeat
Can Spero Therapeutics Inc. (2HA) stock test all time highsMarket Risk Report & Free Low Drawdown Momentum Trade Ideas - Newser
Will Spero Therapeutics Inc. (2HA) stock benefit from sector leadership2025 Top Gainers & Free Weekly Watchlist of Top Performers - Newser
Why Spero Therapeutics Inc. stock is popular among millennials2025 Market Overview & Community Consensus Picks - Newser
How Spero Therapeutics Inc. (2HA) stock behaves in tightening cycles2025 Trading Recap & Intraday High Probability Alerts - Newser
How Spero Therapeutics Inc. stock benefits from global expansionStock Surge & Risk Adjusted Buy/Sell Alerts - Newser
How Spero Therapeutics Inc. (2HA) stock performs during market turbulenceJuly 2025 Reactions & Short-Term High Return Strategies - Newser
Published on: 2025-12-02 04:03:46 - Newser
Will Spero Therapeutics Inc. (2HA) stock remain on Wall Street radar2025 Price Momentum & Reliable Volume Spike Trade Alerts - Newser
Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Tops Revenue Estimates - MSN
Spero Therapeutics announces inducement grant under Nasdaq listing rule - MSN
Spero Therapeutics (NASDAQ:SPRO) Upgraded to “Buy” at Wall Street Zen - Defense World
Can Silver Oak India Limited Maintain Its Share of Global Market for Its ProductStock Buy Signals & Get Free Training on Technical Indicators - earlytimes.in
Spero Therapeutics (SPRO) Awards New Employee with Restricted St - GuruFocus
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Enidnews.com
Breakout Move: Will Spero Therapeutics Inc. stock reach all time highs in 2025 - moha.gov.vn
Aug Mood: Will Spero Therapeutics Inc. stock reach all time highs in 2025July 2025 Patterns & AI Forecasted Entry and Exit Points - moha.gov.vn
Spero Therapeutics (NASDAQ:SPRO) Shares Cross Above 200-Day Moving Average – Should You Sell? - Defense World
Global NTM Infections Pipeline Poised for Growth as Breakthrough Therapies Advance Toward Late-Stage Development, states DelveInsight - The Globe and Mail
What is Spero Therapeutics Inc (SPRO) Stock Return on Shareholders’ Capital? - Setenews
Why Spero Therapeutics Inc. (2HA) stock is favored by hedge fundsJuly 2025 Final Week & Free Weekly Chart Analysis and Trade Guides - newser.com
Will Spero Therapeutics Inc. stock attract ESG investorsWeekly Trade Recap & Verified Swing Trading Watchlists - newser.com
How Spero Therapeutics Inc. (2HA) stock reacts to stronger dollarBear Alert & Low Drawdown Momentum Trade Ideas - newser.com
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):